Previous studies have attributed functional consequences to ARID1A-loss in the context of MYCN-amplified tumours [28], and some authors have postulated ARID1A as the main driving tumour suppressor in 1p36-lost MYCN-amplified cases [46]. The gene discussed is ARID1A; the disease is neoplasm.